Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the resubmission of the Biologics License Application (BLA) for ...
In the third quarter of 2025, the Company expects to present data from its ongoing Phase I/II studies of AMT-130 in support of a potential BLA submission. The update will include follow-up data on all ...
Announced alignment with the U.S. Food and Drug Administration (FDA) on key elements of the Accelerated Approval pathway for AMT-130 in Huntington's disease; Initiated preparations for a potential Bio ...
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
M. Gillheeney, Sr. continued: “We expect to meet a key strategic milestone in 2025 by delivering the ReNu BLA submission by the end of the year. We believe this is a transformational opportunity for ...
The Registrar General of the Bombay High Court on Thursday informed the Court that the Central Project Coordinator is working ...
Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT), a fully integrated, late-stage biotechnology company advancing a sustainable ...
ENLIGHTEN-Fibrosis and ENLIGHTEN-Cirrhosis Phase 3 trials in patients with non-cirrhotic (F2-F3) and compensated cirrhotic (F4) metabolic ...
Transitioned lead commercial responsibility of Nuvaxovid COVID-19 vaccine to Sanofi beginning with the 2025-2026 season Achieved total revenue of $88 million in ...
The company posted adjusted earnings per share of $0.04 for the fourth quarter, beating the analyst estimate of -$0.01. Revenue came in at $126.7 million, surpassing the consensus forecast of $109.6 ...
Scholar Rock Holding Corporation. ( NASDAQ: SRRK) Q4 2024 Earnings Conference Call February 27, 2025 8:15 AM ET Jay Backstrom - President & CEO Ted Myles - COO & CFO Tracey Sacco - Chief Commercial ...
TipRanks on MSN3h
Intellia Therapeutics’ Earnings Call: Progress and ChallengesIntellia Therapeutics Inc (($NTLA)) has held its Q4 earnings call. Read on for the main highlights of the call. Intellia Therapeutics’ Earnings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback